Tune Therapeutics, an epigenome-editing company based in Durham and Seattle, will be the first to initiate a human clinical trial for an epigenetic therapy for a common infectious disease.
Hepatitis B virus (HBV) has a narrow host range, mainly infecting hominoids. A new study reveals the structural differences in the liver cell receptor (NTCP) between humans and monkeys, explaining why ...